ASMB

Assembly Biosciences, Inc. (ASMB) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2026. Assembly Biosciences, Inc. is a biotechnology company developing therapeutics for viral and liver diseases. The company operates as a single segment and relies heavily on its strategic collaboration with Gilead Sciences, Inc. (Gilead). As of June 30, 2026, the company had no approved products and continued to incur operating losses while advancing its clinical pipeline.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Increase: Collaboration revenue increased 39% in Q2 2026 compared to Q2 2025. This was driven by the timing of activities under the Gilead Collaboration Agreement and a $5.1 million cumulative catch-up adjustment recognized in Q2 2026 due to revised estimates of future costs.
• Expense Reduction: Total operating expenses decreased slightly (7% in Q2, 4% YTD) primarily due to lower external program expenses for the 5366 and 6250 candidates, reflecting the completion of certain clinical trials and reduced manufacturing costs. This was partially offset by higher employee-related expenses and stock-based compensation.
• Improved Net Loss: Net loss narrowed significantly year-over-year (62% reduction in Q2, 32% reduction YTD), largely attributable to the revenue catch-up adjustment and reduced R&D spend.
• Capital Raise: In May 2026, the company completed an underwritten offering raising approximately $108.1 million in net proceeds. Gilead participated in this offering, purchasing 471,698 shares for $12.5 million.
• Investment Activity: Net cash used in investing activities was $97.5 million for the six months ended June 30, 2026, primarily due to the purchase of marketable securities using proceeds from the May financing.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities ($320.4 million) are sufficient to fund operations into late 2028. The company expects its cash runway to extend into 2029 upon receipt of a $75.0 million extension fee from Gilead due in Q4 2026.
• Pipeline Updates:
  • HPI Program (5366/1179): Gilead exercised its option in December 2025 to exclusively license this program. Gilead selected 1179 to advance to a Phase 2 study expected to initiate by end of 2026. Gilead does not intend to develop 5366 further at this time.
  • 6250 (HDV/CLD): Phase 2 initiation for Hepatitis Delta Virus (HDV) is expected in Q4 2026. The program was expanded into Cholestatic Liver Diseases (CLD), with Phase 2 initiation expected in Q1 2027.
  • 4334 (HBV): Gilead declined to exercise its option in March 2026. Assembly retains full control and is seeking a partner; the company does not plan to advance 4334 without a partner.
  • 7272: Undergoing regulatory filing-enabling studies for transplant-related herpesviruses.
• Key Risks:
  • Collaboration Dependency: Significant reliance on Gilead for funding, development, and commercialization of key assets. Conflicts or termination of the collaboration could materially harm the business.
  • Profitability: The company has no approved products and expects to continue incurring substantial losses. Future financing may be required.
  • Regulatory & Clinical Risk: Clinical studies are expensive and may fail to demonstrate safety or efficacy. Regulatory approval is uncertain.
  • Third-Party Reliance: Dependence on CROs and third-party manufacturers, including those outside the U.S., introduces supply chain and operational risks.

Investor Verification Checklist

• Verify the sustainability of the $5.1 million revenue catch-up adjustment and its impact on future revenue recognition under the Gilead Collaboration Agreement.
• Confirm the timeline and budget for the Phase 2 study of 1179 controlled by Gilead and the status of the "Profit-Share" opt-in decision.
• Assess the progress of partnering efforts for 4334 given Gilead's decision not to exercise its option.
• Monitor the company's cash burn rate relative to the projected runway into late 2028/2029, especially in light of the upcoming $75 million Gilead extension fee.
• Review the stock-based compensation expense trends, which increased significantly due to performance-based RSUs granted in mid-2025.